Large clinical study establishes nu.q® nets h3.1 as an independent predictor of 28-day mortality in sepsis

Henderson, nev. , jan. 30, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its nu.q®nets h3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (rrt) in sepsis and septic shock patients.
VNRX Ratings Summary
VNRX Quant Ranking